SCHEMBL14973170

SCHEMBL14973170

CCOC(=O)c1cnn(C)c1-c1cnn(-c2ccc(F)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
LMNA P02545 1/20 0.49
ALDH1A1 P00352 8/20 0.46
HPGD P15428 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 1/20 0.41
CA12 O43570 3/20 0.40
CA9 Q16790 3/20 0.40
CHRNA7 P36544 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14973279 0.89 RAB9A (0.49) RAB9ANPC1LMNAALDH1A1SMN1; SMN2
SCHEMBL14973016 0.88 MAPT (0.46) RAB9ANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL14973098 0.88 CA12 (0.51) RAB9ANPC1LMNAALDH1A1SMN1; SMN2
SCHEMBL15750737 0.86 ALDH1A1 (0.56) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL14973182 0.83 GRM4 (0.45) RAB9ANPC1KDM4E
SCHEMBL1194458 0.77 NPC1 (0.59) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL11890412 0.76 ALDH1A1 (0.71) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL14937840 0.73 GRM4 (0.46)
SCHEMBL14972922 0.72 MAPKAPK2 (0.55) RAB9ANPC1LMNAALDH1A1SMN1; SMN2
SCHEMBL6052295 0.72 NPC1 (0.66) RAB9ANPC1LMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A RAB9A 1090/4885NPC1 964/4885LMNA 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.